drugset
drugset / Trial / NCT03389659

XELOX/mFOLFOX Plus Vitamin D3 vs. XELOX/mFOLFOX as Firstline Chemotherapy in mCRC

NCT03389659 ↗

Phase 3 Unknown 750 enrolled Tianjin Medical University Cancer Institute and Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

The study is a randomized,multicenter, double-blinded,phase III study. To explore the affection of vitamin D3 in combination with oxaliplatin plus fluoropyrimidine versus oxaliplatin plus fluoropyrimidine as first-line chemotherapy in previously untreated advanced or metastatic colorectal cancer.

Timeline

Start
2018-02
Primary completion
2021-12
Completion
2022-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Cholecalciferol Other / unclassified 2000 iu Oral

Indications

No indication recorded.